Recombinant Human SLC25A5 Protein, N-GST & C-His from ProteoGenix; catalogue ARO-P10804; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The Recombinant Human SLC25A5 Protein, also known as Adenine Nucleotide Translocator 2 (ANT2), is a mitochondrial membrane protein that plays a crucial role in cellular energy metabolism. This protein is encoded by the SLC25A5 gene and is highly conserved across species, with 96% homology between humans and mice. Recombinant SLC25A5 Protein is produced through genetic engineering techniques, making it a valuable tool for research and therapeutic applications.
The primary structure of Recombinant Human SLC25A5 Protein consists of 298 amino acids, with a predicted molecular weight of approximately 32 kDa. It has six transmembrane domains and a central hydrophilic loop that contains the substrate binding site. This structure is essential for the transport of adenine nucleotides, such as ATP and ADP, across the inner mitochondrial membrane.
Recombinant SLC25A5 Protein is produced in a variety of expression systems, including bacteria, yeast, and mammalian cells. It is typically purified using chromatography techniques, resulting in a highly pure and active protein suitable for research and therapeutic use.
The primary function of Recombinant Human SLC25A5 Protein is to transport adenine nucleotides across the inner mitochondrial membrane. This transport is essential for cellular energy production, as ATP is the primary source of energy for most cellular processes. The activity of Recombinant SLC25A5 Protein is regulated by the mitochondrial membrane potential and the ratio of ATP to ADP in the cell.
In addition to its role in energy metabolism, Recombinant SLC25A5 Protein has been shown to have other functions, including regulation of cell death and involvement in cancer progression. Studies have also suggested a potential role for this protein in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s.
Recombinant Human SLC25A5 Protein has a wide range of applications in both research and therapeutic settings. Its role in cellular energy metabolism makes it a valuable tool for studying mitochondrial function and dysfunction. It can also be used to investigate the role of SLC25A5 in various diseases, such as cancer and neurodegenerative disorders.
In therapeutic applications, Recombinant SLC25A5 Protein has shown potential as a target for cancer treatment. Studies have demonstrated that inhibiting the activity of this protein can lead to decreased cancer cell proliferation and increased cell death. Additionally, Recombinant SLC25A5 Protein has been investigated as a potential therapeutic target for neurodegenerative diseases, with promising results in animal models.
In summary, Recombinant Human SLC25A5 Protein is a crucial mitochondrial membrane protein involved in cellular energy metabolism. Its structure, activity, and potential applications make it a valuable tool for research and therapeutic purposes. As our understanding of the role of SLC25A5 in various diseases continues to grow, the use of Recombinant SLC25A5 Protein is likely to increase, leading to further advancements in the field of mitochondrial biology and medicine.
ProteoGenix catalogue number ARO-P10804. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 32.30 kDa; Fragment: Gln39-Asn74; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
